This clinical trial is focused on studying the effects of a medication called Aficamten (also known by its code name CK-3773274) in patients with a heart condition known as Hypertrophic Cardiomyopathy (HCM). HCM is a disease where the heart muscle becomes abnormally thick, which can make it harder for the heart to pump blood. The purpose of this study is to gather information on the long-term safety and how well patients tolerate Aficamten when used to treat symptoms of HCM.

Participants in the study will take Aficamten in the form of a film-coated tablet, which is taken orally. The study will monitor patients over a period to observe any side effects or changes in their condition. The study aims to ensure that Aficamten is safe for long-term use and to understand how it affects the heart’s function in people with HCM. The study will also compare the effects of Aficamten with a placebo to determine its effectiveness.

Throughout the study, researchers will keep track of any adverse events, which are any unwanted effects that occur during the trial. They will also monitor the heart’s performance, specifically looking at the heart’s ability to pump blood effectively. This will help determine if Aficamten can be a safe and effective treatment option for people living with symptomatic HCM. The study is designed to provide valuable insights into the management of this heart condition and improve treatment options for patients in the future.